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Abstract
Background: With advancing age, thymic efficiency shows progressive decline due to thymic involution allowing
impaired cell-mediated immunity and the appearance of age-related diseases. The intrinsic cause of thymic involution is
still undefined. Chronic inflammation and high glucocorticoids (GCs) may be involved. However, transgenic mice, with
increased GC sensitivity and over expression of GC receptors, display delayed age-associated thymic involution. This
fact suggests that other substances may affect thymic involution. Among them, both isoforms of metallothioneins (MTs)
I+II and III are the major candidates because their increments leads to organ atrophy in constant stress and are induced
by IL-6, which increases in ageing. Enhanced MTs in ageing allows constant sequester of zinc ions and no subsequent zinc
release leading to low zinc ion bioavailability for thymic efficiency. This sequester is very limited in very old age. Thus, we
have investigated the MTmRNA (I+II and III) in the thymus from young, old and very old mice.
Methods: MTmRNA and IL-6mRNA (RT-PCR) in the thymus from different donors were tested. Concomitantly, TECs
proliferation, zinc ion bioavailability (ratio total thymulin/active thymulin), thymulin activity and corticosterone were
tested from different donors.
Results: Both isoforms of MTmRNA and IL-6mRNA increase in old thymus coupled with low zinc ion bioavailability,
reduced TECs proliferation, impaired thymulin activity and enhanced plasma corticosterone in comparison with young.
Conversely, although the thymus is involuted in very old mice because of no changes in thymus weight in comparison to
old mice, reduced MTmRNA, especially MT-I+II isoforms, and low IL6mRNA occur. Concomitantly, good zinc ion
bioavailability, maintained TECs proliferation, satisfactory thymulin activity and reduced corticosterone are observed in
very old mice.
Conclusions: The concomitant increments by high IL-6 of both MT isoforms in the thymus from old mice may be
involved in thymic involution because provoking low zinc ion bioavailability, which is relevant for thymic efficiency. By
contrast, the limited increments of MTs by low IL-6 induce good zinc ion bioavailability and satisfactory thymic efficiency
in very old mice. Therefore, abnormal increased MTs may provoke complete thymic involution during ageing and the
possible appearance of age-related diseases. If their increments are instead limited by low inflammation, healthy ageing
and longevity may be reached.
Published: 12 November 2004
Immunity & Ageing 2004, 1:5 doi:10.1186/1742-4933-1-5
Received: 18 October 2004
Accepted: 12 November 2004
This article is available from: http://www.immunityageing.com/content/1/1/5
© 2004 Mocchegiani et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Immunity & Ageing 2004, 1:5 http://www.immunityageing.com/content/1/1/5
Page 2 of 7
(page number not for citation purposes)
Introduction
The thymus gland is a central lymphoid organ in which
bone marrow-derived T cell precursors undergo a complex
process of maturation and differentiation leading to
migration of positively selected thymocytes to the T cell-
dependent peripheral areas [1]. Although thymocytes pro-
liferation and differentiation persist throughout life, they
diminish with ageing. Older thymuses are significantly
atrophied and have fewer thymocytes than younger ones.
Therefore, the thymus undergoes an age-dependent
degenerative process, which allows a progressive loss of
thymocytes as well as thymic lymphoid tissue becoming
involuted, atrophic and full of fat [2]. Thymic involution
is particularly important in relation to immunosenes-
cence because leading to an impaired T cell-mediated
immunity with the subsequent appearance of some age-
related diseases [3]. The loss of thymocytes in ageing is
also due, other than to diminished size of thymic cortex,
to decreased production of thymic hormonal factors,
which are important for thymocytes maturation, differen-
tiation and proliferation [4]. Thymic hormonal factors,
such as thymulin, thymopentin and thymosines, are pro-
duced by the Thymic Epithelial Cells (TECs), which
number and proliferation decrease in ageing together with
thymocytes [5]. The following one another of thymic neg-
ative events during ageing have been attributed to con-
comitant increments of glucocorticoids (GCs). Specific
GCs receptors are present both on thymocytes and TECs
leading the thymic cells to undergo apoptosis via Fas [6].
However, it has been recently reported in transgenic mice
with increased GC sensitivity and over expression of GC
receptors, a delayed age-associated thymic involution
when compared with wild-type mice. These mice display
a higher number of thymocytes and, surprisingly, thymic
apoptosis is unaffected [7]. These data suggest that endog-
enous GCs may not be directly involved in thymic atrophy
in ageing or, at least, they may act concomitantly or syn-
ergistically with other substances. In this context, some
proteins, such as zinc-bound metallothioneins (MT) (iso-
forms I+II and III), may be involved in age-related thymic
involution for the following reasons. Firstly, MT induc-
tion is controlled by GCs and pro-inflammatory cytokines
(IL-6) [8], which increase in ageing and inflammation [9];
and also high IL-6 is involved in thymic dysregulation
[10]. Second, MT increases in ageing and strictly related to
high IL-6 and GCs [11]. Third, high MT are harmful in
immunosenescence because they sequester zinc and are
unable, within old lymphocytes, in the zinc release [11],
which is in turn pivotal for immune efficiency and in con-
ferring biological activity to thymulin [12], and thymulin
activity, immune efficiency and free zinc ion bioavailabil-
ity decrease in ageing [13]. Fourth, concomitant incre-
ments of MT-I+II and III during persistent stress like-
conditions, as it occurs in ageing [14], lead to pancreas
atrophy in stressed mice [15]. Although, MT-III isoform
may be only present in the brain [16], its existence also in
peripheral organs has been reported [17]. Following these
considerations, we have investigated the presence of MT
I+II and III gene expression and zinc content in the thy-
mus from young, old and very old mice. Concomitantly,
the IL-6 gene expression and TECs number and prolifera-
tion in the thymus from different donors have been eval-
uated as well as thymulin activity, corticosterone and zinc
plasma levels. We have chosen very old mice because the
MT (I+II) gene expression is low, like in younger, allowing
satisfactory peripheral immune response [11].
Materials and Methods
Mice
Balb/c male inbred mice were used at the age of 2–3
months (young = n.10 mice), at the age of 20 months (old
= n.10 mice) and at the age of 28–30 months (very old =
n.10 mice). Although the maximum thymus sizes as well
as peaks in thymocytes maturation and differentiation
occur at 2–4 weeks of age in mice [18], no differences in
thymulin activity and TECs number exist among 1 and 2–
3 months of age [19]. Therefore, the choice of young mice
at 2–3 months of age for the present study is appropriate.
Mice were housed in plastic non-galvanized cages (5–6
mice for cage) and fed with standard pellet food (Nossan,
Italy) and tap water ad libitum. Under our housing condi-
tion, the life span of Balb/c mice was of 30 months [13].
Since about 50% of survival occurred at 20 months of age,
mice at this age were considered old [13]. Mice were main-
tained on a 12-h light/12-h dark cycle from 7:00 a.m. to
7:00 p.m. at constant temperature (20 ± 1°C) and humid-
ity (50 ± 5%). Mice were sacrificed under ether anaesthe-
sia. Heparinized blood samples were collected by cardiac
puncture for plasma determinations of corticosterone,
thymulin and zinc. Freshly thymuses were frozen in liquid
nitrogen for MT-I+II, MT-III and IL-6 mRNA expressions
and for testing zinc content.
RNA isolation and RT-PCR analysis
Total RNA was extracted from frozen thymus using Tri-
Reagent according manufacture s protocol (Sigma, USA).
3 µg of RNA sample were reverse transcribed adding Olio
d(T) and kept at 70°C for 10 min. dent, Raise inhibitor
and MMLV reverse transcriptase were subsequently added
and incubated at 37°C for 1 h. Samples were heated at
95°C to inactivate enzymes and stored at 20°C. PCRs
were performed using sense and antisense primers as fol-
lows: MT-I: 5'-ATGGACCCCAACTGCTCCTGCTCCACC-
3', 5'-GGGTGGAACTGTATAGGAAGACGCTGG-3' (259
bp) MT-III:5'-ATGGACCCTGAGACCTGCCCCTGTCCT-
3', 5'-GGCCTCTGCCTTGGCCCCCTCTTCACC-3',(183
bp); β-actin: 5'-GGACTCCTATGTGGGTGACGAGG-3', 5'-
GGGAGAGCATAGCCCTCGTAGAT-3' (366 bp); IL-6: 5'-
ATGAAGTTCCTCTCTGCAAGAGACT-3', 5'-CACTAG-
GTTTGCCGAGTAGATCTC-3' (615 bp). Conditions forImmunity & Ageing 2004, 1:5 http://www.immunityageing.com/content/1/1/5
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amplification were as follows: for MT-I each cycle con-
sisted of 94°C 0.30 min, 50°C 0.30 min, 72°C 0.30 min
with 30 cycles; for MT-III each cycle consisted 94°C 45
sec., 55°C 30 sec., 72°C 1.5 min with 30 cycles; for β-actin
each cycle consisted 94°C 1 min, 61°C 1 min, 72°C 1
min with 24 cycles; for IL-6 each cycle consisted 94°C 1
min, 65°C 2 min, 72°C 3 min with 40 cycles. The prod-
ucts of amplification were size-fractionated by 2% agarose
gel electrophoresis and visualized by staining with ethid-
ium bromide. Semi-quantitative analysis of the amplified
products was performed with an image analyser (Gel-doc
2000 instrument, Bio-Rad, USA). The results were evalu-
ated as a relative unit determined by normalisation of the
density of each band to that of the β-actin one. This
method reflects MT protein production tested with Ag+
saturation method [11].
Plasma Active Thymulin (AT) and total thymulin (TT)
Plasma active zinc-bound thymulin (AT), as extensively
described elsewhere [19], was measured using a bioassay
based on the ability to restore the inhibitory effect of aza-
thioprine on rosette formation in spleen cells from young
Tx mice. Results were expressed as log-2 of the maximal
dilution of tested plasma able to induce this phenomenon
[19]. In order to avoid interference due to zinc, zinc sul-
phate at final concentration of 200 nM was added up to
plasma samples. This fact shows the total amount of thy-
mulin produced (active thymulin+ inactive thymulin)
(TT) [19]. The ratio TT/AT is an index of zinc ion bioavail-
ability because of strict inverse correlation between ratio
TT/AT and plasma zinc levels. In particular, ratio >2 = low
zinc ion bioavailability; ratio <2 = mild zinc ion bioavail-
ability; ratio = 1 normal zinc ion bioavailability [19].
Plasma zinc and thymus zinc content
Plasma and tissue zinc content were determined in
Atomic Absorption Spectrophotometer (AAS) against zinc
reference standards (Sigma USA). Plasma zinc was deter-
mined after plasma dilution 1:5. Thymus tissue (1 gr) was
put in muffle furnace at 550°C overnight. The ash
obtained was diluted with 3 ml of 3 N HCl and transferred
to a 25 ml volumetric flask and further diluted with 3 ml
of 0.36 N HCl. The determination of zinc was then per-
formed at AAS.
Plasma Corticosterone
Plasma corticosterone level (ng/ml) was determined by
RIA rat-corticosterone-3H kit (ICN Biomedicals, CA, USA)
and referred against a standard curve. The percentage of
cross-reaction with other steroid was <0.01. The sensitiv-
ity was of 0.05 ng/ml of corticosterone.
Immunocytochemistry studies
a) TECs characterization
Anti pan-cytokeratin IgG1/FITC MoAb (Sigma, USA)
diluted 1/25 and anti-keratin MoAb (Sigma, USA) diluted
1/20 were used. For this latter, guinea pig IgG/FITC
(Sigma, USA) diluted 1/60 was used as second antibody.
These MoAbs are specific to detect TECs (cortical and
medullary) [20].
b) TEC separation and percentage
TECs were separated with method described by Kurz et al.
[20]. Briefly, the thymus from young, old and very old
mice after 6 h of culture was minced into small fragments
and incubated with collagenase (1 mg/ml, Sigma, USA) in
PBS for 1 hr at 37°C (1 ml of collagenase solution/thy-
mus). The choice of 6 h of culture is because the maxi-
mum thymulin production and TECs number and
proliferation occurred at this time of culture in experi-
ments of thymulin kinetic (from 1 h to 12 hrs) from
young thymic cultures [21,22].
The suspension was then centrifuged (2 min, 400 g) and
the pellet suspended in 1 ml of Dulbecco s modified Eagle
medium/Ham s F12 medium (1:1) (DMEM/F12, Gibco,
Germany). The cells were subjected to two-steps trypsin
(0.1 and 0.25%, respectively) and 0.001% DNase treat-
ment in order to avoid fibroblasts [19]. After three washes
in PBS, the cells were dissociated by cautious triturating
through Eppendorf tips and incubated in 3 ml of DMEM/
F12 medium for 2–3 h at 37°C in humidified 5% CO2-
atmosphere in order to make to adhere the cells. The
supernatant containing unattached TEC was seeded into
another plastic flask containing DMEM/F12 medium sup-
plemented with 10% horse serum and put in culture in
humidified 5% CO2-atmosphere. The cultures were
inspected for morphologically visible fibroblasts (spindle
shaped cells). In cases of significant contamination, the
cells were washed with PBS and underwent again to
trypsinization [20]. Separated TECs were washed three
times in PBS. An aliquota (103) was resuspended in 1 ml
of medium and underwent to TEC percentage analysis.
Percentages of separated TECs were counted in 1.000 cells
at fluorescence microscope [22]. Tests were performed
after pre-fixation with cold methanol in the slides. Con-
trols were performed without the primary antibodies.
c) TECs proliferation
After TECs separation, another aliquota (40 × 103) was
resuspended in 4 ml of DMEM/F12 medium for TEC pro-
liferation analysis, which was approached using [3H] thy-
midine incorporation using 96 microtiter plates (Nunc,
Denmark). 40 × 103 TECs were put in 40 wells (100 µl/
well = 103 TECs/well). 10 wells were used as young; 10
wells as old; 10 wells as very old. Concomitantly, 1 µCi
[3H]-thymidine/well (Amersham, UK) was added. TheImmunity & Ageing 2004, 1:5 http://www.immunityageing.com/content/1/1/5
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plates were incubated in humidified 5%-CO2 atmosphere
for 6 hrs. Automatic harvester collected the samples and
the amount of incorporated radioactivity was determined
in a liquid scintillation beta-counter (Perkin-Elmer, USA).
Statistical analysis
Two-tailed Student s t test, and ANOVA test (one-way)
evaluated differences between means. Correlations were
determined by linear regression analysis by the least
square method. Differences were evaluated by analysis of
covariance. Differences were significant when p < 0.05.
Results
MT-(I+II and III) and IL-6 mRNAs and zinc content in the 
thymus from young, old and very old mice
Table 1 shows that MT-I+II and MT-III increase in old
mice in comparison with young (p < 0.001). The same
increment is also observed in very old mice as compared
to young ones (p < 0.01), but at lower levels than old
especially for MT-I+II. The increments of both isoforms of
MT in old mice are correlated with high gene expression
of IL-6 when compared to young mice (p < 0.01). The
increments of IL-6 from the thymus of very old mice are
lower, but still significant when compared to young (p <
0.05). Conversely, the zinc content within the thymus is
very high in old mice as compared to young and very old
mice (p < 0.01). Since AAS tests zinc-bound and zinc
unbound [12], this last finding is not so surprising
because it suggests that a large amount of zinc ions are
bound to MT in the thymus from old mice. As a conse-
quence, free zinc ions are not available for thymic effi-
ciency in old age. Significant positive correlation exists
between zinc content and MT-I+IImRNA from the thymus
of young, old and very old mice (r = 0.83, p < 0.01). The
thymus weight from old and very old mice is strongly
reduced in comparison to young mice (p < 0.001), but
with no changes between old and very old mice (Table 1).
Thymic efficiency, plasma zinc and Corticosterone in 
young, old and very old mice
Table 2 shows that thymulin activity is strongly reduced in
old mice in comparison with young (p < 0.001). Thymu-
lin activity is instead satisfactory in very old mice when
compared to old ones (p < 0.05), even if its plasma value
does not reach to that observed in young mice (Table 2).
These data reflect the number (in percent) and the prolif-
eration of TECs. Both TECs number and proliferation are
reduced in old mice when compared to young and very
old mice (p < 0.01), even if the TECs proliferation is lower
in very old mice than in young ones, but still significant in
comparison with old mice (p < 0.05) (Table 2). The pro-
liferation data in young mice agree with testing TECs pro-
liferation in pure murine TECs cell line (IT-45RI), as
previously shown [21].
The ratio total thymulin (TT)/active thymulin (AT) repre-
sents the zinc ion bioavailability. More high is the ratio (≥
2) less zinc ion bioavailability is present, whereas ratio <
2 or equal to 1 means satisfactory or good zinc ion bioa-
vailability, respectively [19]. The ratio TT/AT is higher in
old mice in comparison with young and very old mice (p
< 0.01) (Table 2). This fact means that a good zinc ion
bioavailability exists in very old mice, as in younger ones,
despite plasma zinc levels are lower in very old mice than
in young ones (p < 0.01) and, at the same time, not differ-
ent to those observed in old mice (Table 2). With regard
to plasma Corticosterone, higher values are observed in
old mice when compared to young and very old mice (p
< 0.01) (Table 2).
Significant inverse correlation exists between zinc and
Corticosterone (r = -0.71, p < 0.01), whereas significant
positive correlation exists between thymulin activity and
TECs number and proliferation (r = 0.81, p < 0.01; r =
0.79, p < 0.01, respectively) from young, old and very old
mice.
Discussion
Although MT-III isoform may be present exclusively
within the brain [16], some peripheral organs (testis,
prostate, epididymis, tongue, ovary, uterus, stomach,
heart, pancreas and seminal vesicles) may also express
MT-III isoform together with MT-I+II [17]. We herein
present for the first time the concomitant gene expression
Table 1: MT-I+II, MT-III, IL-6 mRNAs and zinc content in the thymus from young, old and very old mice.
Mice MT-I+II (MT-I/
βactin)
IL-6 (IL-6/
βactin)
MT-III (MT-III/
βactin)
Zinc content (µg/gr.) Absolute thymus weight 
(mg)
Young 0.18 ± 0.02 0.14 ± 0.03 0.48 ± 0.02 62.3 ± 11.2 30.6 ± 5.0
Old 3.52 ± 0.3* 0.23 ± 0.02§ 1.65 ± 0.03* 107.4 ± 27.5** 13.6 ± 2.0§
Very old 1.29 ± 0.6+ 0.18 ± 0.04+ 1.63 ± 0.02* 77.4 ± 8.7 15.4 ± 2.3§
*p < 0.001 when compared to young mice; +p < 0.01 when compared to old mice;
**p < 0.01 when compared to young and very old mice; §p < 0.01 when compared to young mice;
++p < 0.05 when compared to old miceImmunity & Ageing 2004, 1:5 http://www.immunityageing.com/content/1/1/5
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of MT-I+II and MT-III also in the thymus. Both isoforms
of zinc-bound MT (I+II and III)mRNA increase within the
thymus of old mice, but with a minor extent of MT-I+II
isoform in the thymus from very old mice. Concomi-
tantly, the gene expression of IL-6 is higher in old mice
than in young and very old ones. The zinc content within
the thymus is enhanced in old mice respect to young and
very old mice, whereas some thymic functions (thymulin
activity and TECs number and proliferation) are impaired
in old mice and preserved in very old mice. These last
findings regarding to zinc content and thymic efficiency
seems contradictory between old and very old mice.
Really, they are not contradictory. Since AAS tests zinc-
bound and zinc-unbound [13], the higher zinc content in
the old thymus is largely due to high zinc-bound MTs,
which recall zinc from the periphery, via zinc transporters
ZnT1–4 [23], and sequester a lot amount of zinc ions [22].
The inflammation provokes zinc loss with subsequent
impairment of immune response [24]. Thus, such a recall
and sequester by MT are due to the great inflammation by
high IL-6 and GCs because zinc ions have not to be lost.
But, free zinc ions are subsequently not available for
thymic efficiency due to inability of MT in zinc release in
constant inflammation [14]. Conversely, limited recall of
zinc ions occurs in very old mice because the inflamma-
tion is less deep. As a consequence, the zinc content in the
thymus from very old mice is lower and, at the same time,
more free zinc ions are available for thymic efficiency by
low zinc-bound MT. Anyway, the present data show that
abnormal increments of both isoforms of MT are present
in the atrophic thymus from old and very old mice, but
with less extent of MT-I+II in very old mice.
MT-I+II and III are expressed in the brain with a balance
between the two isoforms (25). When one isoform
increases, the other decreases due to a possible genetic
control of MRE region on the chromosome 8, which
brings the two isoforms [26]. Concomitant increments of
the two isoforms within the hippocampus from old rats
leads to impaired number and functions of synapses cou-
pled with low zinc ion bioavailability [27]; and synaptic
function is zinc-dependent [28]. The same phenomena
occur in age-related neurodegenerative diseases [29], sug-
gesting a possible role of increased MT-I+II and III in neu-
rodegeneration [27]. Moreover, the concomitant presence
of MT isoforms provokes the atrophy of the pancreas in
stressed mice [15]. Therefore, enhanced MT I+II and III in
the old thymus may lead to the thymic involution and
atrophy because of an unbalance between the two MT iso-
forms. The mechanism may be largely due to the constant
sequester of zinc ions by MT (I+II and III) with no subse-
quent zinc release leading to low zinc ion bioavailability
for thymic endocrine activity and TECs proliferation [13].
In this context, IL-6 and glucocorticoids (GCs) may play
key roles because IL-6 and GCs affect MTmRNA [8] and,
in turn, abnormal high GC levels are involved in thymic
atrophy through the activation of GC receptors on TECs
and thymocytes [6]. A lack of free zinc ions also provokes
thymic atrophy [30]. We have found enhanced IL-6mRNA
within the thymus from old mice. Concomitantly, strong
increments of plasma corticosterone are observed. Such
increments are strictly related to high MTmRNA and low
zinc ion bioavailability. These findings suggest that the
chronic inflammation, via IL-6 and GCs, allows high MTs
induction, low zinc ion bioavailability and subsequent
thymic atrophy in old mice. The thymus is obviously
atrophic in very old mice. But, the MT-I+IImRNA and IL-
6mRNA are lower than old mice as well as reduced corti-
costerone. High corticosterone provokes zinc loss by urine
and faeces [31]. Corticosterone is low in very old mice
(Table 2). Thus, very old mice display more free zinc ion
bioavailability with subsequent more thymic efficiency
and preserved TECs number and proliferation. TECs pro-
duce thymulin, a zinc-dependent thymic hormone [12].
Zinc-bound MTs transfer zinc to thymulin in TECs [32].
The less MT-I+IImRNA in very old mice may thus allow
less sequester of zinc ions. Alternatively, an easier release
of zinc by MT for thymic efficiency might occur due to
reduced inflammation by low IL-6mRNA and
corticosterone. Anyway, the thymus from very old mice is
still efficient despite it is involuted because the thymus
weight between old and very old mice does not change
(Table 1). This means that the thymic reconstitution in
old age might not be necessary because the age-related
loss of thymic efficiency appears to be only quantitative
and not qualitative [33]. Thus, it might be sufficient to
Table 2: Zinc ion bioavailability, corticosterone, thymulin and TECs number and proliferation in young, old and very old mice
Mice Thymulin 
activity (log-2)
AT/TT (log-2 (zinc ion 
bioavailability)
Corticosterone 
(ng/ml)
Plasma zinc 
(µg/dl)
% TECs TECs proliferation 
(cpm)
Young 5.5 ± 0.5 1.1 ± 0.3 153 ± 18.3 110 ± 11 53 ± 11 750 ± 25
Old 1.07 ± 0.3* 3.0 ± 0.3** 265 ± 16.6** 80 ± 5.7++ 21 ± 7** 227 ± 34**
Very old 2.5 ± 0.3+ 1.0 ± 0.3 180 ± 12.4+ 87 ± 43++ 40 ± 12+ 450 ± 39+
*p < 0.001 when compared to young mice; +p < 0.05 when compared to old mice;
**p < 0.01 when compared to young and very old mice; ++p < 0.01 when compared to young mice.Immunity & Ageing 2004, 1:5 http://www.immunityageing.com/content/1/1/5
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maintain inflammatory status and MTs homeostasis
below a critical threshold in order to preserve thymic effi-
ciency. Further experiments in thymic output from very
old mice and in genes involved in thymocytes maturation
and differentiation (Rag 1 and Rag 2) [2] are in progress
in our lab.
On the other hand, MT-ImRNA is lower in lymphocytes
from human nonagenarians coupled with satisfactory
thymic and peripheral immune efficiency and good zinc
ion bioavailability [11]. Moreover, very old mice display
still efficient thymic functions during liver regeneration
after partial hepatectomy (model of acute and constant
inflammation) [34]. In addition, the presence of invo-
luted thymus in stressed MT transgenic mice [22] further
supports the involvement of high MT in thymic involu-
tion during ageing.
However, the thymic involution is not irreversible phe-
nomena because zinc treatment in old mice restores
thymic efficiency with a re-growth of thymic cortex [19].
This finding suggests that in ageing the thymus is in qui-
escent phase, which is less deep in very old age due prob-
ably to more zinc ion bioavailability, via MTs
homeostasis, and less inflammation. Indeed, zinc also
affects cell cycle and, therefore, cellular proliferation [35].
Thus, the thymus from very old mice is still active and not
quiescent. The satisfactory zinc ion bioavailability cou-
pled with the maintenance of TECs proliferation in the
thymus from very old mice is in line with this interpreta-
tion. This means that in vivo condition TECs from very
old mice are still capable to proliferate at the occurrence,
for example in presence of external noxae in order to have
a sufficient thymulin production for a prompt immune
response, as occurring in human centenarians, who are
high responder individuals showing a great capacity in
remodelling thymulin activity [36].
In conclusion, concomitant increments of zinc-bound
MT-I+II and III within the thymus may lead to thymic
involution in ageing because they sequester zinc and are
unable in the subsequent zinc release, which is indispen-
sable for thymic efficiency. The cause may be related to
chronic inflammation by high IL-6 and GCs. Without
excluding a direct role of GCs in thymic involution [6],
GCs may synergistically act with MT isoforms because
GCs also affect MTmRNA [8]. Less inflammation by low
IL-6 and GCs in very old mice allows reduced MTmRNA
with subsequent satisfactory zinc ion bioavailability and,
therefore, preserved thymic efficiency.
However, if the thymic involution may be a necessary
event in order to avoid autoimmune phenomena in age-
ing is an intriguing point to be investigated. Indeed, high
IL-6 provokes an enlargement of the thymus with the
appearance of autoimmune phenomena [10]. Thus, if on
one hand high MTs may be of protection inducing thymic
involution in order to escape autoimmune phenomena
by high IL-6, on the other hand high MT are harmful
because leading to low zinc ion bioavailability for thymic
efficiency. However, in this context, the involvement of
zinc and MT in the efficiency of extrathymic T-cell path-
way [13] has to be also considered, because this pathway
is prominent in ageing and autoimmunity in order to
compensate thymic failure [37]. Very old mice display sat-
isfactory thymic efficiency (present study) and good
extrathymic T-cell functions [38]. Moreover, thyroid
autoantibodies are rare in healthy centenarians [39].
Therefore, the thymic involution, via MTs homeostasis,
has to be limited or controlled concomitantly with the
appearance of efficient extrathymic T-cell functions in
order to reach healthy ageing and longevity. In other
words, a correct balance between thymic involution and
extrathymic T-cell functions has to exist in ageing. Other-
wise, a complete thymic atrophy by abnormal high MT-
I+II and III, via high IL-6 may provoke continuous
immune dysfunctions (thymic and extrathymic). Altered
genetic controls between the two MT isoforms on MRE
region of chromosome 8 may be involved, representing
an interesting field of investigation in immunosenes-
cence. Works are in progress in our lab.
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